Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 3/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3518675 | 0.96 | MLLT1 (0.44) | MEN1KMT2AKDM4EGAATSHR | |
| SCHEMBL50840 | 0.91 | MLLT1 (0.50) | MEN1KMT2AKDM4EGAATSHR | |
| SCHEMBL83409 | 0.90 | MLLT1 (0.52) | MEN1KMT2AKDM4EGAATSHR | |
| SCHEMBL14550565 | 0.88 | GAA (0.45) | MEN1KMT2AKDM4EGAATSHR | |
| SCHEMBL3519685 | 0.88 | SMN1; SMN2 (0.43) | MEN1KMT2AGAATSHRHSD17B10 | |
| SCHEMBL61188 | 0.81 | TNKS2 (0.50) | KMT2AKDM4EGAATSHRHSD17B10 | |
| SCHEMBL51858 | 0.81 | KDM4E (0.41) | KMT2AKDM4EGAATSHRHSD17B10 | |
| SCHEMBL3520029 | 0.79 | KDM4E (0.45) | MEN1KMT2AKDM4EGAATSHR | |
| SCHEMBL3515927 | 0.79 | KDM4E (0.40) | KMT2AKDM4EGAATSHRHSD17B10 | |
| SCHEMBL50996 | 0.78 | KMT2A (0.41) | MEN1KMT2AKDM4EGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141429-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | EISAI INC. (US) | 2015-05-21 | — | — | US | disclosed |
| EP-2842956-A1 | PARP inhibitor compounds, compositions and methods of use | Eisai Inc. (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8894989-B2 | PARP inhibitor compounds, compositions and methods of use | EISAI INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20130011365-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | EISAI INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-8236802-B2 | PARP inhibitor compounds, compositions and methods of use | EISAI INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236802-B2 | PARP inhibitor compounds, compositions and methods of use | EISAI INC. (US) | 2012-08-07 | — | — | US | disclosed |
| EP-2209375-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Eisai Inc. (US) | 2010-07-28 | — | — | EP | disclosed |
| US-20090098084-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MGI GP, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090098084-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MGI GP, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2009046205-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | EISAI RESEARCH INSTITUTE (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141429-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PARP1, PARP3, PARP2 | MEN1 1486/4885KMT2A 483/4885KDM4E 891/4885 |
| US-20090098084-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PARP1, PARP3, PARP2 | MEN1 1486/4885KMT2A 483/4885KDM4E 891/4885 |
| US-20130011365-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PARP1, PARP3, PARP2 | MEN1 1470/4885KMT2A 491/4885KDM4E 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.